This is a randomized, controlled trial to evaluate the efficacy of treatment with DHPG (12/mg/kg/day) versus no treatment in neonates with symptomatic congenital cytomegalovirus and CNS disease. Only babies with symptomatic congenital infection who stand to derive therapeutic benefit are eligible for the study.
Showing the most recent 10 out of 570 publications